- MEI Pharma (NASDAQ:MEIP) FY16 results: Revenues: $0; R&D Expense: $13.4M (-43.7%); SG&A: $7.6M (-14.6%); Operating Loss: ($21M) (+36.0%); Net Loss: ($20.9M) (+36.1%); Loss Per Share: ($0.61) (+47.4%); Quick Assets: $45.9M (-28.1%).
- No guidance given.
MEI Pharma net loss improves in FY16
Recommended For You
About MEIP Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| MEIP | - | - |
| MEI Pharma, Inc. | ||